At 10 weeks gestational age, 10–15% of cell‑free DNA in maternal plasma is trophoblastic in origin rather than maternal; which maternal serum screening test for fetal aneuploidy is based on this phenomenon?

Cell-Free DNA (cfDNA) Screening for Fetal Aneuploidy

The maternal serum screening test based on the presence of 10-15% trophoblastic cell-free DNA in maternal plasma at 10 weeks gestation is cell-free DNA screening (also called noninvasive prenatal testing or NIPT). 1

Understanding the Biological Basis

Cell-free DNA screening exploits a fundamental biological phenomenon:

• After 10 weeks of gestation, approximately 10-15% of total cfDNA in maternal plasma is of placental origin (derived from trophoblast cells), while the remaining 85-90% is maternal in origin 1
• These are small DNA fragments (<200 base pairs) that are free-floating in the plasma 1
• The placental-derived cfDNA can be analyzed to determine the probability of fetal chromosomal conditions 1

How the Test Works

The technology uses next-generation sequencing combined with bioinformatic algorithms:

• Massively parallel shotgun sequencing: All extracted cfDNA is sequenced, each fragment is localized to its chromosome of origin, and fragments from each chromosome are counted—additional material from a given chromosome increases the probability of an extra copy 1
• Targeted sequencing: Counts chromosome fragments from a limited subset of the genome for greater efficiency and lower cost 1
• Single nucleotide polymorphism analysis: Analyzes thousands of SNPs to determine genotype and relative copy number of chromosomes of interest 1

Clinical Performance

cfDNA screening demonstrates superior accuracy compared to traditional screening methods:

For Common Trisomies:

• Trisomy 21 detection rate: >99% with false-positive rate of 0.04% 1
• Trisomy 18 detection rate: 98.83% with false-positive rate of 0.07% 1
• Trisomy 13 detection rate: 92.85% with false-positive rate of 0.04% 1

This contrasts sharply with traditional first-trimester combined screening (detection rate 77-82% for trisomy 21 with 3-5% false-positive rate) 1

Positive Predictive Values:

• Trisomy 21: 91.8% overall, varying from 45% in low-risk to 96% in high-risk patients 1
• Trisomy 18: 65.8% 1
• Trisomy 13: 37.2% 1
• When diagnostic testing confirms abnormal cfDNA screens: 93% for trisomy 21,64% for trisomy 18,44% for trisomy 13, and 38% for sex chromosomal abnormalities 1

Critical Limitations and Pitfalls

Test Failure:

• Overall failure rate: 0.9-8.1% of cases, with 8% overall but 16% in cases with fetal aneuploidy 1
• Low fetal fraction is the primary cause, associated with maternal obesity (20% failure rate in women >250 lb, 50% in women >350 lb) 1
• Failed tests carry 9.2-fold increased odds ratio for aneuploidy, particularly trisomies 13,18, and triploidy—these patients should be offered diagnostic testing 1

False-Positive Results:

Common causes include 1:

• Confined placental mosaicism
• Vanishing twin or nonviable cotwin
• Maternal sex chromosomal mosaicism
• Maternal malignancy with chromosomal abnormalities in tumor cells

What cfDNA Does NOT Screen For:

• Neural tube defects or other structural abnormalities associated with elevated maternal serum alpha-fetoprotein 1, 2, 3
• Many other chromosomal abnormalities beyond common trisomies—16.9% of all chromosomal abnormalities detected by traditional screening followed by diagnostic testing would be missed by cfDNA alone 1

Clinical Recommendations

According to SMFM/ACOG guidelines, cfDNA screening is recommended for women at increased risk for fetal aneuploidy 1:

1. Maternal age ≥35 years at delivery
2. Fetal ultrasound findings indicating increased aneuploidy risk
3. History of previous pregnancy with trisomy 13,18, or 21
4. Positive traditional aneuploidy screening results
5. Parental balanced Robertsonian translocation with increased risk of trisomy 13 or 21

More recent ACMG guidelines (2023) recommend NIPS over traditional methods for trisomy screening in both singleton and twin gestations 1

Essential Counseling Points

All patients must understand 1:

• cfDNA is a screening test, not diagnostic—abnormal results require confirmation with chorionic villus sampling or amniocentesis before any management decisions
• A negative result decreases but does not eliminate risk of aneuploidy
• The test does not screen for all chromosomal conditions
• Patients desiring definitive information should be offered diagnostic testing directly
• Maternal serum alpha-fetoprotein screening or ultrasound evaluation must still be offered to assess for neural tube defects and structural abnormalities 1, 2, 3

Timing and Practical Considerations

• Testing can be performed at or after 10 weeks gestation 1, 4, 5
• Results typically available within 14 days in 98% of cases 5
• Repeat sampling after initial failure yields results in 50-80% of cases 1
• Not recommended in pregnancies with vanishing twin due to high risk of false-positive results from aneuploid demised twin 1
• Limited data and lower performance in multifetal gestations—routine use not recommended in this population 1